Antiva Biosciences bags $22 mln Series C
South San Francisco-based Antiva Biosciences Inc, a biopharmaceutical company, has raised $22 million in Series C financing. Brace Pharma Capital led the round with participation from NS Investment, Osage University Partners, Alexandria Venture Investments, Canaan Partners and Sofinnova Ventures. In addition to the funding, Vinzenz Ploerer, president and CEO of Brace Pharma Capital has been appointed to Antiva's board of directors.
28 March 2017•1 min read
